Answers are grounded in this paper and cite their sources.
I read with interest the recent article by Volpe et al.1 on the natural history of 32 incidentally detected small renal masses. The authors stated that small renal masses grow at slow or undetectable rates and that a period of observation may be appropriate for some patients. I would like to point out, however, that the study was somewhat limited in that none of the tumors were analyzed on biopsy and only nine were resected. Tumors were presumed to be renal cell carcinomas (RCCs) on the basis of imaging studies, which are not infallible in distinguishing RCCs from benign tumors such as oncocytomas and angiomyolipomas. In fact, one of the nine resected tumors in the study was confirmed to be an oncocytoma. Volpe and colleagues concluded that tumor growth rate on its own probably was not sufficient for the accurate prediction of the behavior of every small renal mass. Furthermore, they speculated that studies (cytogenetic, immunohistochemical, and other) performed on needle biopsy samples, as well as the investigation of novel radiographic parameters, could help in the identification of patients who had renal lesions exhibiting favorable prognostic characteristics and a long natural history and who therefore could be followed conservatively in most cases. It is worth noting that pathologists, and especially cytopathologists, already use fine-needle aspiration and core-needle biopsy to distinguish patients who can be followed conservatively from those who should undergo resection.2 As Volpe et al.1 point out, recent studies have found that as many as 38.5% of all masses measuring < 2 cm are benign. Benign lesions such as angiomyolipomas can be identified on fine-needle aspiration or core-needle biopsy, as can RCC subtypes such as chromophobe RCC and low-grade papillary RCC, which are associated with a significantly lower risk of disease progression compared with conventional RCC. Conventional/clear cell tumors with high Fuhrman grade, in contrast, are associated with a relatively poor prognosis and probably should be resected if at all possible, regardless of their size. Some other minor issues also warrant mentioning. Volpe and colleagues state that the biologic behavior of predominantly cystic RCC is not well known, when it is in fact well documented that these tumors are relatively indolent.3 It is true that in the past, the term adenoma was used by pathologists to describe renal masses that measured < 3 cm, were detected incidentally at autopsy, and were histologically similar to RCC but had lower associated metastasis rates.4 The current definition of adenoma according to the 1996 American Joint Committee on Cancer Consensus Conference, however, is very different, and based on this definition, adenomas specifically do not include radiographically identified masses.5 There remain specific settings in which growth rate may be useful in predicting outcome for patients with small, radiographically identified lesions. These settings include Fuhrman Grade 1 or 2 conventional RCC and extensively cystic Bosniak Grade 2 or 3 disease, which may be difficult to diagnose reliably using either fine-needle or core-needle biopsy. Correlation of the results presented by Volpe et al. with the additional findings discussed in the current correspondence may be useful.
No takes yet. Share an insight, caveat, or question.
Andrew A. Renshaw (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: